Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): A multicenter, double-blind, prospective trial

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2766-2772

  Jiang, Z F ^a   Cristofanilli, M ^b   Shao, Z M ^c   Tong, Z S ^d   Song, E W ^e   Wang, X J ^f   Liao, N ^g   Hu, X C ^c   Liu, Y ^a   Wang, Y ^h   Zeng, L ⁱ   Zhang, M ⁱ  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f ZHEJIANG CANCER HOSPITAL   (China)

^g GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^h PEKING UNION MEDICAL COLLEGE   (China)

ⁱ JOHNSON AND JOHNSON   (United States)

Author keywords

Circulating tumor cells; Metastatic breast cancer; Overall survival; Progression free survival

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOMODULATING AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHINESE; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HER2 POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

CIRCULATING TUMOR CELLS; METASTATIC BREAST CANCER; OVERALL SURVIVAL; PROGRESSION-FREE SURVIVAL;

ADULT; CHINA; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84887126401     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt246     Document Type: Article

References (20)

1. Gradilone A, Naso G, Raimondi C et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 2011; 22: 86-92.
2. Ring A, Smith IE, Dowsett M. Circulating tumour cells in breast cancer. Lancet Oncol 2004; 5: 79-88.
3. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
4. Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging- predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-6409.
5. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-1430.
6. Liu MC, Shields PG, Warren RD et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009; 27: 5153-5159.
7. Dawood S, Broglio K, Valero V et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 2008; 113: 2422-2430.
8. Giuliano M, Giordano A, Jackson S et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011; 13: R67.
9. Giordano A, Giuliano M, De Laurentiis M et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012; 23: 1144-1150.
10. Hwang SB, Bae JW, Lee HY et al. Circulating tumor cells detected by RT-PCR for CK-20 before surgery indicate worse prognostic impact in triple-negative and HER2 subtype breast cancer. J Breast Cancer 2012; 15: 34-42.
11. Munzone E, Botteri E, Sandri MT et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer 2012; 12: 340-346.
12. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Nolé F, Munzone E, Zorzino L et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008; 19: 891-897.
15. Maestro LM, Sastre J, Rafael SB et al. Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer Res 2009; 29: 4839-4843.
16. Nakamura S, Yagata H, Ohno S et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010; 17: 199-204.
17. Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012; 23: 618-624.
18. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-3373.
19. Liu MC, Mego M, Nakamura S et al. Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). J Clin Oncol 2011; 29(S15): 10592.
20. Zhang KX, Kim C, Chow E et al. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2. Breast Cancer Res Treat 2011; 125: 89-97.